Novavax, Inc. (NVAX) — closed signal from March 12, 2026
Partial Published before the outcome was known, scored automatically when the window closed on June 10, 2026.
Predicted vs. what happened
What happened
Reached 43% of the predicted growth at its peak, without hitting the target.
The thesis — published March 12, 2026
Novavax is getting real results now: it reported unexpected profit and struck a licensing deal with Pfizer, which together make the company look like it can execute rather than just survive. Those developments reduce near-term worry about the balance sheet. If biotech sentiment stays calm, buying on small dips could offer upside in the next quarter.
Primary drivers
- Unexpected profit made the company more believable
- Pfizer deal adds clearer revenue prospects
- Price pattern favors buying on small pullbacks
- Company progress looks better than sector noise
How it played out
NVAX: target was not reached
Lyra published NVAX at $10.45 on 2026-03-12, with a short-term expectation of 26% growth. The thesis pointed to unexpected profit, a Pfizer licensing deal, clearer revenue prospects, a price pattern that favored small pullbacks, and company progress that looked better than sector noise.
Inside the window, NVAX rose to a peak of $11.61 on 2026-05-27, a gain of 11.1%. That stayed below the $13.17 target. It never got there. By 2026-06-10, the stock ended at $8.56. The thesis partially played out on the move higher, but missed the published target and finished below the publication price.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.